Journal article

Cost Effectiveness of Eplerenone in Patients with Chronic Heart Failure

Zanfina Ademi, Kumar Pasupathi, Henry Krum, Danny Liew

AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS | ADIS INT LTD | Published : 2014

Abstract

BACKGROUND: Chronic heart failure (CHF) remains an important cause of morbidity and mortality worldwide. Currently, there are no cost-effectiveness studies of eplerenone use in patients with New York Heart Association (NYHA) class II CHF. OBJECTIVE: We sought to evaluate the cost effectiveness of eplerenone compared with placebo in patients with chronic systolic heart failure and NYHA class II symptoms. METHODS AND RESULTS: A 10-year Markov model with yearly cycles was constructed to evaluate the cost effectiveness of eplerenone compared with placebo, based on data from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure) study. The model classifi..

View full abstract